Lianhuan Pharmaceutical (600513.SH): Buprenorphine injection and other medications are expected to be selected for national centralized drug procurement.

According to the announcement from Zhitong Finance APP, Lianhuan Pharmaceutical (600513.SH) stated that the company and its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., participated in the bidding work for the 12th batch of national centralized drug procurement organized by the National Organization Drug Procurement Office. According to the public announcement of the proposed selection results for the 12th batch of national organized drug centralized procurement released by the procurement office, the company and its holding subsidiary, Changle Pharmaceutical, have been selected for the following drugs in this centralized procurement: oral regular-release formulation of Measartan, injection of Bumetanide, and injection of Vitamin B6.